List view / Grid view
Drug delivery refers to approaches for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect.
Viral vectors to deliver gene therapies are utilised by clinically approved therapies. However, this method is not the only option for advanced therapeutics. In this piece, Brent Warner, President, Gene Therapy at Poseida Therapeutics, discusses the balance between efficacy and safety in gene therapy, highlighting positive pre-clinical data for non-viral…
In this section, Dr Peter O’Toole, University of York, examines innovation in the field of microscopy for drug discovery and development research, while in an exclusive Q&A, Dr Michael Grange, Rosalind Franklin Institute, discusses the advantages of utilising cryo-electron tomography imaging.
Researchers have developed a novel class of therapeutics, called feedback disruptors, that could have the potential to be resistance-proof drugs.
Scientists have engineered a new class of material which is able to both withstand the harsh acidic conditions of the stomach and then dissolve predictably in the comparatively gentle environment of the small intestine.
Scientists have gained new insights into the way G protein-coupled receptors operate, a step toward the development of improved drugs with fewer side effects.
Scientists at the Endocrine Society have found extracellular vesicles may offer new insights into treating endocrine disorders.
A new biodegradable gel can release drugs and special antibodies that simultaneously deplete macrophages from the surgical site and activate T cells.
Scientists have developed a delivery method that enhances treatment by adding CAR T cells and specialising signalling proteins to a hydrogel that is injected next to a tumour.
New research has shown iron-like compound holds promise for treating patients with glioblastoma, an aggressive brain cancer.
Looking at disease through a patient’s memory B cells can reveal vulnerabilities within pathogens. In this article, Dr Purnanand Sarma, President and Chief Executive Officer of Immunome, explores how advancements in memory B-cell antibody-based treatments will improve our understanding of how these cells can aid in fighting cancer and other diseases.
By studying the gut microbes of rats, researchers discovered that a bacteria known as Coprococcus comes contributes to resistance to high blood pressure drugs.
Dr John Lewis, CEO of Entos Pharmaceuticals, outlines how an innovative proteolipid platform could enable a new class of DNA-based vaccines in this article.
This ebook includes articles about antibody-based therapies that could protect against cancer by utilising a patient's memory B cells. Also included is a piece on an intranasally-delivered monoclonal antibody treatment to potentially protect against SARS-CoV-2.
Included in this ebook are articles on how to develop more effective CAR T cells by modifying the CAR design and why recent findings about ferroptosis in cancer cells could enhance immunotherapies.
Dr Sheraz Gul reviews the drug approvals from 2021 and highlights the novel modalities of molecules that target KRAS and HIF-2α, which have historically been considered as undruggable.
